Valuation : Kamada Ltd.

Market Cap 1.41B 0 465M 400M 377M 344M 642M 44.44B 648M 4.49B 1.73B 22.54B 1.75B 1.71B 71.59B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.41B 0 465M 400M 377M 344M 642M 44.44B 648M 4.49B 1.73B 22.54B 1.75B 1.71B 71.59B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.1x
Free-Float
54.48%
Yield 2026 *
-
Yield 2027 * -
1 day-1.53%
1 week-1.13%
Current month+0.08%
1 month+14.37%
3 months+14.26%
6 months-12.02%
Current year+8.50%
1 week 2,443
Extreme 2443
2,546
1 month 2,013
Extreme 2013
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2015
Director of Finance/CFO 56 31/12/2017
Chief Operating Officer 54 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Exercice

VP Quality

6,937 0.0120%
2/9/26 Exercice

Founder

107,166 0.1857%
26/8/26 Exercice

VP Quality

68,328 0.1184%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-1.13%+2.29%+18.91% 474M
-1.78%-5.95%+42.72%-4.51% 80.65B
-0.87%-3.73%-18.38%-37.45% 59.12B
+0.74%-8.23%+461.99%+26.92% 54.14B
-2.00%-3.66%-10.49%+27.83% 50.1B
-1.42%-8.61%-3.21%+144.43% 45.33B
+2.23%-4.04%+51.06%-16.82% 31.14B
-2.17%-3.69%+42.93%+92.69% 25.54B
-1.48%-9.18%-4.22%+142.82% 21.8B
-0.99%-4.61%+62.88%+102.21% 16.06B
Average -1.19%-4.13%+62.76%+49.70% 38.44B
Weighted average by Cap. -1.30%-4.76%+78.84%+34.94%

Financials

2026 *2027 *
Net sales 606M 0 199M 171M 162M 147M 275M 19.03B 278M 1.92B 740M 9.65B 748M 731M 30.67B 673M 0 221M 190M 180M 164M 306M 21.15B 308M 2.14B 823M 10.73B 831M 813M 34.07B
Net income 84.8M 0 27.86M 23.96M 22.61M 20.6M 38.5M 2.66B 38.85M 269M 104M 1.35B 105M 102M 4.29B 104M 0 34.21M 29.42M 27.76M 25.29M 47.28M 3.27B 47.71M 331M 127M 1.66B 128M 126M 5.27B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
10/09/26 ILA 2,452.00 -1.53% 69,336
09/09/26 ILA 2,490.00 +0.08% 130,011
08/09/26 ILA 2,488.00 -0.12% 317,225
07/09/26 ILA 2,491.00 0.00% 57,863
04/09/26 ILA 2,491.00 +0.44% 90,400
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!